Cutaneous leishmaniasis (CL) heals spontaneously within several weeks or months, but, in rare cases, CL-active lesions last for many years. In this study, we assessed cell-mediated immunity in non-healing CL through the measurement of three pro-inflammatory cytokines: Interferon-c (IFN-c), IL-17a and CXCL-11. For this, 32 patients afflicted with healing or non-healing CL were recruited in this study. Peripheral blood mononuclear cells (PBMCs) of every patient were treated with three antigens: purified protein derivative (PPD), soluble Leishmania antigen (SLA) and phytohaemagglutinin (PHA). Cytokine quantification was performed using enzyme-linked immunosorbent assay (ELISA) method. Results of our study showed that neither cytokine produced in the presence of a PPD stimulator (as an irrelevant antigen) significantly differed between the healing and non-healing groups (P-value ≥0.05 for all of them). However, IFN-c, CXCL-11 and IL-17a levels produced in the presence of PHA or SLA were significantly higher within the healing than in the non-healing group (P-value <0.01 for all of them). It seems that appropriate levels of IFN-c, as well as IL-17a and CXCL-11, contribute to the control of Leishmania infection.
Introduction
Cutaneous leishmaniasis (CL) is recognized as a neglected tropical disease, but its incidence has risen in recent years. This disease is endemic in 98 countries, where 1,500,000 new cases occur each year; however, about 70% of them are attributed to Colombia, Brazil, Algeria, Afghanistan and the Middle Eastern countries, especially Iran (1, 2).
Leishmania major (L. major), Leishmania tropica (L. tropica) in the old world as well as species belonging to Leishmania mexicana (L. mexicana) complex and subgenus of Leishmania Viannia, in the new world, are assumed to be the most aetiological factors of the CL (2, 3) . This disease is transmittable through female sand flies and commonly results in localized lesions. In general, lesions of CL heal spontaneously within a few weeks or months; nevertheless, in rare cases, CL-active lesions last for many years. Persistent lesions of CL, which are called the non-healing form of cutaneous leishmanias (NHCL), do not respond to conventional chemotherapy (4, 5) .
Vast bodies of research carried outwith animal modelling confirmed that interferon-gamma (IFN-c), which promotes innate immunity against intracellular organisms, yield favourable outcome in case of Leishmania infection. For example, C57BL/6 mice tending towards the TH1 paradigm in response to Leishmania infection produce high levels of IFN-c, leading to sound immunity and selflimited lesions (6) . Leishmanicidal activity of IFN-c is, however, supported by IL-17a cytokine produced by TH17 cells. These cells protect mucosal and skin tissue of Leishmania-infected mice through neutrophil and monocyte recruitment (7, 8) .
Furthermore, CXCL-11, which is the major ligand of CXCR3, has a critical role in TH1 cell-mediated immunity. This cytokine recruits leucocytes in the infected sites and activates IFN-c producing T cells and NK cells (9) . In human CL, however, protective role of IFN-c is poorly understood. Moreover, to the best of our knowledge, no report concerned crucial roles of IL-17a and CXCL-11 cytokines NHCL. This study was carried out to determine whether there was an appropriate cut-off value of an IFN-c release assay for diagnosis of NHCL cases. In addition, the authors aimed to investigate the association of NHCL with IL-17a and CXCL-11, which were considered as two pro-inflammatory cytokines for IFN-c production.
Material and methods
This was a cross-sectional study carried out at the Acquired Immunodeficiency Research Center (Isfahan University of Medical Sciences [IUMS], Isfahan, Iran) from July 2014 to June 2016. All parts of the study protocol were approved by the Ethical Committee of the Hamadan University of Medical Sciences (HUMS), Hamadan, Iran (project number: IR.UMSHA.REC.1395.120). The study procedure was clearly explained to the participants or their guardians, and informed consent was obtained from them. Patients' information, study groups, and sample size. The inclusion criteria for patient recruitment were as follows: (1) age 5-60 years, (2) active lesion indicating clinical signs of CL, (3) absence of any chronic condition. Exclusion criteria were participants with (1) pregnancy, (2) history of malignancy, (3) steroid intake. CL in all of the patients was confirmed through the Giemsa-stained smear or Leishmania culture method.
The number of cases afflicted with the NHCL (as a rare disease) was limited; hence, we aimed to provide three controls per case. As a matter of practicality, we recruited eight patients afflicted with the NHCL and 24 controls affected by active lesions of CL. NHCL cases were afflicted with active lesions that were more than 2 years old. Patients were considered to have the healing form of CL met the following criteria: (1) the lesions were properly cured in less than 1 year, and (2) no clinical sign of CL was detected during a 9-month follow-up after the complete healing. To avoid the adverse effects of Leishmania treatment on the patients' immune response, the blood sampling in the healing group preceded chemotherapy. All of the patients were from the Isfahan Province (Iran), and L. major was considered a causative factor of CL (10, 11) .
Leishmanin Skin Test (LST). LST was carried out using test and control vials prepared by the Pasteur Institute, Tehran, Iran. Each test vial included 6 9 10 6 bodies of killed L. major promastigotes suspended in 0.01% thiomersal within phosphate-buffered saline (PBS). Control vials included 0.01% thiomersal in PBS. These vials were kept in a refrigerator (4°C) until use. To perform LST, we separately injected test and control solutions in the volar surfaces of the left and right arms. Each dose, containing 0.1 ml of the suspension, was injected through a 27-gauge needle. After 48 h, the skin induration was measured with a ballpoint. LST results were classified in the following three groups: negative (≤5 mm), positive (6-14 mm) and strongly positive (≥15 mm).
Preparation of Soluble Leishmania Antigen (SLA). SLA was prepared through a protocol, which was described by Khamesipour et al. with some modifications (12) . Briefly, 5 9 10 6 L. major promastigotes were washed in 1 ml of sterile PBS. The parasites were subjected to seven cycles of freezing and thawing followed by sonication. Lysed bodies of the parasites were centrifuged at 30,000 g for 20 min, and the extracted supernatant was kept at À70°C until the administration. The concentration of SLA was determined using the Bradford assay. Culture of PBMCs. Heparinized blood was collected (10 ml) from every participant, and the PBMCs were isolated with Ficoll-Hypaque (Biocoll, Biochrom AG, Berlin, Germany) density centrifugation. The isolated PBMCs of each patient were put in a 12-well flat-bottom plate and distributed in three wells differing in their antigen components. 5 PBMCs in a total volume of 1 ml. Our cell culture medium comprised the RPMI-1640 complete medium supplemented with 10% heat-inactivated foetal bovine serum (FBS), 20 units/ml penicillin, 20 lg/ml streptomycin and 584 mg/l L-glutamine (all from Sigma, Germany). These cultures were kept in 12-well, flat-bottom plates (1 ml/well) in an atmosphere of 5% CO2 at 37°C. After 72 h, the culture supernatant was harvested and stored at À20°C for cytokine evaluation.
Cytokine assay. The IL-17a and CXCL-11 in the harvested supernatants were quantified through sandwich enzyme-linked immunosorbent assay (ELISA) by appropriate Biolegend commercial kits (San Diego, CA), by following the instructions provided by the manufacturer (IL-17a catalogue number# 433917 and CXCL-11 catalogue number# 443307). The IFN-c levels of the supernatants were determined through sandwich ELISA method using the eBioscience commercial kit (Ready-SET-Go! â , USA) following the given instructions (catalogue number# 88-7316-22). The levels of IFN-c, IL-17a and CXCL-11 cytokines were calculated on duplicate wells for each sample.
Patient information. The entire demographic and clinical history of the patients comprising the CL treatment type, frequency of antimonial injection (intralesional or systemic), duration of lesion healing, site of Leishmania lesion, area of living, history of travel to endemic areas of leishmaniasis, seasonal onset of CL and smoking habit was logged in specific forms. In the CL healing form, we charted, weight, length, number of the lesions and the lesion size at the time of CL diagnosis. In the NHCL cases, we logged the aforementioned variables at the time of blood sampling or LST implementation. The lesion size was determined through two crossing diameters by metric calliper. The lesion size was reported according to the mean size of the total lesions, provided the patient had multiple lesions.
Statistical analysis. All analyses were performed using the IBM SPSS Statistics for Windows ver. 22.0 (IBM Co., Armonk, NY, USA). Qualitative variables were reported as frequency and percentage, while quantitative variables were described as mean and standard deviation (SD). Correlations between variables were evaluated using Pearson's method. The cut-off point of the IFN-c predicting the healing and non-healing groups was determined by a receiver operating characteristic (ROC) curve analysis. The best cut-off value for predicting patient assignment in the aforementioned study groups was determined on the basis of sensitivity and specificity. Cytokine levels of the different groups and stimulators were compared using Mann-Whitney and Friedman's tests as appropriate. The Pearson chi-square test and Fisher's exact test were used for a comparison of the nominal variables. In addition, the Mann-Whitney and independent t tests were used for a comparison of the categorical and continuous variables. P < 0.05 was considered as statistically significant.
Results

Clinical findings
Mean values of ages in non-healing and healing patients were 38.37 (Standard Deviation [SD] = 21.9) and 33.58 years (SD = 11.45), respectively. Our two groups (healing and non-healing) did not differ significantly from one another in the mean age of the participants (P = 0.569). The median durations of lesion in the healing and non-healing groups were 60 and 925 days, respectively. The minimum interval between the last treatment and sampling in non-healing patients was 18 months. None of the participants was affected by diabetes and hypertension. All the major characteristics of study groups are shown in Table 1 .
LST induration differed significantly between the two groups (P = 0.023). To elaborate, in healing group, 91.7% of the patients were positive, and 8.3% were strongly positive (Table 1 ). In the non-healing group, 50% of the participants were positive, while others were negative. Hands and feet showed the maximum occurrence of CL lesions in healing and non-healing cases (79.2% and 62.5%, respectively). Our groups did not significantly differ from one another in lesion location (P = 0.459).
Cytokine assay
Supernatant levels of IFN-c, IL-17a and CXCL-11 cytokines produced by PBMCs incubated with three different antigens (PPD, SLA and PHA) were compared. IFN-c, IL-17a and CXCL-11 produced in the presence of PPD (as an irrelevant antigen) did not significantly differ between the healing and non-healing groups (the P-values were >0.05). IFN-c, IL-17a and CXCL-11 produced in the presence of PHA or SLA differed significantly between the two groups (P-value <0.01 for all of them) ( Tables 2-4 and Figs. 1-3) . Moreover, we assessed cytokine profile of each group. In the healing group, our results showed that compared to the PPD-incubated cells, IFN-c, IL-17a and CXCL-11 rose significantly in the PHA-and SLA-stimulated wells (P-value ≤0.001 for all of them) (Tables 2-4); furthermore, the PHA-and SLA-treated wells significantly differed from one another in the above-mentioned cytokine levels (P-value ≤0.001 for all of them). In the non-healing group, PHA and SLA incubation led to a rise in the IFN-c, and IL-17a levels, although this increase was not significant (P-value ≥0.05 for all of them) ( Tables 2 and 3 ). However, compared to the PPD-incubated well, the CXCL-11 cytokine increased significantly in the PHA-and SLAincubated wells (P = 0.001) ( Table 4 ). The CXCL-11 did not significantly differ between the SLA-and PHAincubated wells (P ≥ 0.05). The optimal cut-off value for predicting non-healing leishmaniasis in the SLA-stimulated wells was 1208 pg/ml (sensitivity 87.5, specificity 100, area under curve [AUC] 99.5) (Fig. 4) . In addition, there was a moderately positive correlation between the LST induration and levels of IFN-c (r = 0/46, P = 0.008) (Fig. 5) . On the other hand, the IFN-c significantly correlated with IL-17a and CXCL-11 (P < 0.001) (Figs. 6  and 7 ). The Pearson correlation coefficient for relation between IFN-c and IL-17a was 0.86. The correlation between IFN-c and CXCL-11 was 0.64.
Discussion
To show whether persistent lesions of CL was associated with insufficient amounts of IFN-c and its supportive cytokines (such as IL-17a, CXCL-11), we compared the (Figs. 1-3) . We juxtaposed the cytokines produced in the presence of SLA and found that CXCL-11, IL-17a, as well as IFN-c significantly differed between the non-healing and healing groups (Tables 2-4 and Figs. 1-3 ), suggesting that different cytokines produced by the TH1 subset decreased the duration of Leishmaniainduced lesions (4, 5, 13) . Likewise, PHA-stimulated cells of non-healing patients produced low amounts of IFN-c, CXCL-11 and IL-17a, compared to healing patients. These findings indicated that non-healing patients had a lower capacity of in vitro stimulation, even in response to powerful and non-specific mitogen. Low levels of proinflammatory cytokines of nonhealing patients may be attributed to primary immunodeficiency disorders resulting in Th1 impairment; however, the reason for low responses of SLA-and PHAstimulated cells is unclear and warrants further clinical studies (14) .
In PPD-stimulated wells, the levels of proinflammatory cytokines did not significantly differ between the healing and non-healing patients. On the other hand, compared to the SLA-and PHA-incubated wells, the IFN-c as well as IL-17a and CXCL-11 were significantly low in the PPDtreated wells. These findings confirmed that PPD could be considered an appropriate antigen for negative controls. Intriguingly, the IFN-c responses to PPD in all of the healing and non-healing patients were very low, indicating that no participant was recently infected with TB or some of the Mycobacteria, thus avoiding false-positive results being attributed to the above-mentioned infection (15, 16) . Furthermore, our findings showed that the PBMCs of nonhealing patients were not totally unresponsive to SLA or PHA, although these responses were not sufficient.
An association of IFN-c production with the duration of human leishmaniasis had been established in some of the previous studies. For example, Ajdary et al. showed that the PBMCs obtained from non-healing patients produced low amounts of IFN-c in SLA-incubated wells. These researchers applied intracellular staining of pro-inflammatory cytokines and showed that the PBMCs of non-healing patients stimulated with SLA expressed low levels of CD4 and IFN-c proteins (5). Hoseini et al., however, indicated that some non-healing cases might produce high levels of IFN-c. Hence, it seems plausible that other proinflammatory cytokines such as IL-17a may affect the outcome of leishmaniasis (17) .
The results of our study showed that the PBMCs of healing patients produced high levels of IL-17a in response to SLA. In comparison, IL-17a production in non-healing patients was significantly low (Table 3) . Our findings were consistent with those of Novoa et al., who reported an antileishmanial activity of IL-17a. They found higher production of IL-17a in a subclinical form of leishmaniasis (SC) compared to patients with active CL, indicating the participation of IL-17a in the control of Leishmania infection (18) . Consistently, high production of IL-17a has been shown in immune individuals previously exposed to L. major compared to those who were not exposed to Leishmania infection (19) . On the other hand, many bodies of research show that IL-17a induces immunopathological tissue damage, suggesting a destructive role of this cytokine in the lesion healing. In this context, mucosal lesions induced by Leishmania braziliensis (L. braziliensis) contained significantly higher number of IL-17a-expressing cells compared to cutaneous lesions, suggesting an association between IL-17a and the severity of Leishmania infection. Collectively, it seems that IL-17a has a dual permissive and protective role during the Leishmania infection. In fact, regulated levels of IL-17a yield protective immunity against leishmaniasis, whereas extreme levels of this pro-inflammatory cytokine associate with persistent tissue damage (7, 20) .
The results of our study showed that PBMCs of nonhealing patients produced significantly lower amounts of CXCL-11 in response to Leishmania antigen (Table 4 ). This finding indicated supportive role of CXCL-11 against Leishmania infection. Our results were consistent with previous studies, which well-documented positive role of CXCL-11 and its chemokine receptor (CXCR3) in T cell maturation, priming, activation and migrations (21, 22) . It seems that CXCR3 ligands (such as CXCL-11) yield NK cell activation inducing protective immunity against Leishmania infection (23) . In this context, NK cells, which are considered as major source of IFN-c, induce TH1 response in the preliminary phase of Leishmania infection (24, 25) . Interestingly, CXCL-11 producing cells amplify their chemokine production when they are incubated with recombinant IFN-c (23, 26) . We consistently found a positive correlation between IFN-c and CXCL-11 production.
The impacts of CXCL-11-like chemokines (CXCL9 and CXCL10) on the promotion of Th1 immune responses had been previously established. In fact, these chemokines recruit Th1 lymphocytes as well as neutrophils to the Leishmania-infected sites (27) . Not only do CXCL9 and CXCL10 increase inflammation at the Leishmania-infected tissues, but CXCL9 chemokine also gradually destroys the plasma membrane of L. mexicana promastigotes leading to Leishmania lysis. In addition, during Leishmania donovani (L. donovani), Plasmodium falciparum and Trypanosoma cruzi infections, CXCL10 levels are known to rise in the serum of the affected patients, suggesting that CXCL-11-like chemokines, have a critical role in participants affected by parasitological infections (27, 28) .
We carried out LST as a kind of delayed type of hypersensitization (DTH) assay in response to killed L. major promastigotes. The current study showed that not only LST results differed significantly between healing and non-healing patients (P = 0.023), but that there was also a moderate association between positivity of the LST results and IFN-c production (Table 1) . These findings were in agreement with a previous study by Sassi et al., (29) demonstrating that LST-positive individuals had sound immunity against Leishmania antigen associated with the Th1 response and high levels of IFN-c production.
Lesion size was the other clinical variable that differed significantly between healing and non-healing patients (Table 1) . This clinical finding was in accordance with a previous study showing that the healing time of the lesions correlated with lesion size (30) . Consistently, Hurrell et al. (31) showed that higher levels of IFN-c produced in Leishmania lesions induced a decline of the lesion size and parasite load existing in the skin of CL patients.
Pentavalent antimony compounds, considered as the gold standard for CL treatment, evoke no satisfactory responses in chronic cases of the disease. Application of these drugs is associated with unfavourable consequences: cardiac, renal and hepatic toxicity, as well as vertigo, vomiting, skin rash, headache and diarrhoea (32, 33) . In addition, there is no consensus about an appropriate strategy in NHCL cases (33) . As such, we aimed to report the highest specificity in the ROC curve to avoid false positives. For practical reasons, the best cut-off value of IFN-c for the prediction of CL outcome was 1208 pg/ml (sensitivity 87.5, specificity 100, AUC 99.5). This cut-off point could distinguish between nearly 88% of NHCL and other healing cases. In other words, a CL patient should be identified as NHCL if the IFN-c production is ≤1208 pg/ml. In this context, other therapeutic methods Ó 2017 The Foundation for the Scandinavian Journal of Immunology (such as the application of trichloroacetic acid or combined cryotherapy, paromomycin and intralesional meglumine antimoniate), which have higher efficacy in persistent lesions of CL, should be replaced with the conventional regimen of chemotherapy if the patient is recognized as NHCL (33, 34) .
Overall, the data presented in this study well documented the importance of IFN-c, as well as CXCL-11, and IL-17a cytokines in the clinical outcome of human CL. In fact, the cut-off value in the present study could be useful for the identification of NHCL cases. Moreover, this study supports the rationale to perform animal studies, and even clinical trials, aiming to apply recombinant pro-inflammatory cytokines for the treatment of NHCL.
